^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CSF3R (Colony Stimulating Factor 3 Receptor)

    i
    Other names: CSF3R, Colony Stimulating Factor 3 Receptor, Colony Stimulating Factor 3 Receptor (Granulocyte), Granulocyte Colony-Stimulating Factor Receptor, G-CSF Receptor, CD114 Antigen, G-CSF-R, GCSFR, CD114, SCN7
    2ms
    Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. (PubMed, Br J Cancer)
    Our AI model, using only archival histologic slides, accurately predicted postoperative recurrence in PDAC and revealed image features linked to outcomes and gene expression.
    Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor) • IGFBP3 (Insulin-like growth factor binding protein 3)
    2ms
    CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study. (PubMed, Cancer Med)
    CSF3R mutations define a distinct, high-risk AML subset characterized by an inferior treatment response and survival, warranting incorporation into future risk stratification.
    Retrospective data • Journal
    |
    NPM1 (Nucleophosmin 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation
    2ms
    Development and validation of a cell-based methodology to evaluate filgrastim relative affinity to granulocyte colony-stimulating factor receptor. (PubMed, J Immunoassay Immunochem)
    After performing a validation exercise, the method proved to be accurate, specific, and linear within an affinity interval of 75 to 130%; precise with a confidence interval of 93.6 to 114.2% and a coefficient of variation of 12.6%. The validation exercise proved that the proposed cell-based method is a viable alternative to evaluate the biological activity of filgrastim via the affinity for its receptor and it is suitable to be included as part of its biological characterization exercises as well as in comparability exercises for products coming from distinct manufacturing processes.
    Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Neupogen (filgrastim)
    2ms
    LAX1 as a core biomarker in Alzheimer's disease and periodontitis via the STAT signaling pathway. (PubMed, BMC Geriatr)
    LAX1 gates STAT-dependent neuroinflammation and periodontal destruction, offering a druggable checkpoint and blood-based biomarker for these convergent chronic diseases.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CSF3R (Colony Stimulating Factor 3 Receptor) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
    2ms
    Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. (PubMed, Br J Haematol)
    This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • CALR (Calreticulin)
    |
    TP53 mutation • SRSF2 mutation • STAT3 mutation
    2ms
    Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia. (PubMed, EJHaem)
    Larger studies are warranted to evaluate its long-term safety and efficacy. This trial is registered at https://irct.behdasht.gov.ir/ in Iranian Registry of Clinical Trials (IRCT) # IRCT20150125020786N3.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Neulasta (pegfilgrastim)
    2ms
    Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options. (PubMed, Hemasphere)
    The most used agents include hydroxyurea, interferon, hypomethylating agents, and JAK inhibitors, although none of them are disease-modifying. Allogeneic hematopoietic stem cell transplant remains the only potentially curative approach and should be considered in all eligible patients. Actionable mutations (CSF3R, NRAS/KRAS, and KIT) have also been identified, supporting the development of new agents targeting the involved pathways.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • SETBP1 (SET Binding Protein 1) • ETNK1 (Ethanolamine Kinase 1)
    |
    KRAS mutation • NRAS mutation • KIT mutation • ASXL1 mutation • TET2 mutation • EZH2 mutation • CBL mutation • SRSF2 mutation
    |
    hydroxyurea
    2ms
    Case Report: Blood single-cell analysis of a IVB high-grade serous ovarian cancer patient presenting a favorable prognosis. (PubMed, Front Oncol)
    This integrative molecular and phenotypic profiling of blood-derived components identified potentially distinct molecular signatures, such as overexpression of IL12, ANGPT1 downregulation and HIF1A downregulation, in the literature described as linked to the patient's beneficial prognosis. These findings suggest that advanced liquid biopsy techniques may provide complementary insights into prognostic biomarkers and therapeutic targets in HGSOC.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CSF3R (Colony Stimulating Factor 3 Receptor) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDIT4 (DNA Damage Inducible Transcript 4) • PGK1 (Phosphoglycerate Kinase 1)
    3ms
    Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. (PubMed, World J Clin Oncol)
    This WES-AI-ML framework provides mutation-guided therapies for BC-CML, enabling real-time stratification and Food and Drug Administration-approved drug repurposing. While this exploratory study is limited by its small sample size (n = 7), it establishes a methodological framework for precision oncology stratification that warrants validation in larger, multi-center cohorts.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • Pan tumor
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • BCR (BCR Activator Of RhoGEF And GTPase) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Lynparza (olaparib) • Jakafi (ruxolitinib) • Tibsovo (ivosidenib)
    3ms
    Genetic characterization of pediatric B-cell acute lymphoblastic leukemia in Argentina uncovers molecular heterogeneity and novel variants. (PubMed, Front Pharmacol)
    Importantly, we identified novel single nucleotide variants in DUX4, CSF3R and CREBBP, and fusion transcripts. This study not only reports transcriptional heterogeneity in our Latin American cohort but also supports the implementation of open-source bioinformatic pipelines in resource-limited settings to enhance precision diagnosis and guide personalized treatment.
    Journal
    |
    CREBBP (CREB binding protein) • CSF3R (Colony Stimulating Factor 3 Receptor) • DUX4 (Double Homeobox 4)
    3ms
    Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts. (PubMed, medRxiv)
    One variant was classified as of uncertain significance. Our data emphasize the need to integrate gene function, variant type, and effects on the C-terminus to comprehensively evaluate somatic NMDe variants and predict their consequences across adult and pediatric cancer cohorts.
    Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor) • CCND3 (Cyclin D3) • CALR (Calreticulin)
    3ms
    Abnormal RH antigen expression in myeloid malignancies with MPL mutation, CSF3R mutation, or 1p deletion: Evidence of two distinct mechanisms. (PubMed, Transfusion)
    CN-LOH of chromosome 1p, resulting in homozygosity for the MPL mutation, has been previously described in the literature. However, we report here for the first time a link between CN-LOH of chromosome 1p (resulting in homozygosity for the CSF3R mutation) or chromosome 1p deletion and the presence of RH phenotype abnormalities. Furthermore, no alloimmunization was observed despite increased transfusion requirements.
    Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor)